France Halts Valneva's Chikungunya Vaccine for Seniors Amid Health Concerns

Published 2 days agoVALN

France Halts Valneva's Chikungunya Vaccine for Seniors Amid Health Concerns

France's national public health agency, the Haute Autorité de Santé (HAS), recently paused the use of Valneva's chikungunya vaccine, IXCHIQ®, for individuals aged 65 and older. The decision, made on April 25, 2025, followed reports of serious adverse events among elderly patients with existing health conditions during vaccination campaigns in La Réunion and Mayotte.

In the United States, Valneva's IXCHIQ® received FDA approval in November 2023 for adults aged 18 and older who are at an increased risk of chikungunya exposure. By February 2024, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended the vaccine for travelers heading to regions experiencing chikungunya outbreaks. As of May 2025, U.S. health agencies have not amended these recommendations for older populations.

The situation highlights how vaccine guidance can differ from country to country, influenced by local health data and emerging safety reports. While France has reacted to specific case trends in seniors, the U.S. maintains its current level of endorsement. Individuals are advised to check with local health authorities to get the latest guidelines pertinent to their region.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Aurinia Pharmaceuticals Projects 2025 Revenue of up to $260 Million Amid Strategic Restructuring

Aurinia Pharmaceuticals Projects 2025 Revenue of up to $260 Million Amid Strategic Restructuring

4 minutes agoAUPH

Aurinia Pharmaceuticals has announced its revenue guidance for 2025, projecting a range between $250 million and $260 million. This announcement comes as the company undergoes significant operational changes aimed at improving efficiency and reducing costs, as reported by Webull. One of the highlights from Aurinia's recent financial performance is the robust growth in LUPKYNIS sales, which resulted in a 36% increase in net product revenue year-over-year for the third quarter of 2024. To further enhance its operational efficiency, Aurinia is implementing a strategic restructuring plan that includes a workforce reduction by approximately 45%. This effort is expected to save the company over $40 million annually in cash-based operating expenses, according to information from Aurinia Pharmaceuticals' official website. In addition to financial updates, Aurinia is focusing on its pipeline development. The company initiated a Phase 1 study of AUR200, a promising dual inhibitor targeting autoimmune disease-related cytokines, in September 2024. Investors are keeping an eye on the results expected in the first half of 2025. Meanwhile, Aurinia's share price was recently at $8.37, marking a 4.63% rise from the prior close, demonstrating a positive market reaction.

Apple Shares Surge Amid U.S.-China Tariff Reduction Deal

Apple Shares Surge Amid U.S.-China Tariff Reduction Deal

19 minutes agoAAPL

Apple's stock has seen a marked increase following a significant development in U.S.-China trade relations. The two countries have agreed to a temporary reduction in tariffs for a 90-day period. Under this agreement, U.S. tariffs on Chinese imports will be cut down to 30%, while China's tariffs on U.S. goods will fall to 10%. This diplomatic move has improved market sentiment, as reported by the Financial Times. This announcement has had a positive impact on major stock indices, with a notable rally in technology stocks. The S&P 500, Dow Jones, and Nasdaq have all experienced gains, with increases of 2.53%, 2.51%, and 3.34% respectively. Reuters highlighted that Apple, a leading tech stock, saw its shares rise by 6.2%. As of May 12, 2025, Apple's stock is trading at $209.74, reflecting a $11.21 increase from the previous close. In a strategic shift to counteract trade challenges, Apple is moving a significant portion of its iPhone production for the U.S. market to India. This decision aims to reduce the impact of tariffs and maintain competitive production costs. Additionally, Reuters noted that Apple is contemplating an increase in iPhone prices for its upcoming models, introducing new features and designs to justify a potentially higher price point of up to $1,142, a substantial rise from the current $799 entry price.

U.S.-China Trade Truce Sends Funko's Stock Skyrocketing

U.S.-China Trade Truce Sends Funko's Stock Skyrocketing

34 minutes agoFNKO

Funko's stock has seen a remarkable surge following the announcement of a 90-day trade truce between the U.S. and China, which includes significant reductions in tariffs. The U.S. has agreed to cut additional tariffs on Chinese imports from 145% down to 30%, while China will lower tariffs on U.S. goods from 125% to just 10%. These temporary measures are intended to last for 90 days, according to Reuters. The trade truce has sparked a significant rally in U.S. markets. The S&P 500 has climbed by 2.6%, the Dow Jones jumped 957 points, marking a 2.3% increase, and the Nasdaq rose by an impressive 3.6%, as reported by AP News. This positive market response highlights investor optimism as the trade tensions show signs of easing. Toy manufacturers like Funko, who previously struggled with high tariffs that led to price hikes and complicated supply chains, are expected to benefit from the reduced tariffs. This truce alleviates some of the pressures faced by the industry, offering a sense of relief and potential stability for companies heavily reliant on international trade.

Amazon Stock Surges After U.S.-China Tariff Easing

Amazon Stock Surges After U.S.-China Tariff Easing

49 minutes agoAMZN

Amazon's stock saw a notable increase after the U.S. government announced a reduction in high tariffs as part of a 90-day truce with China. The U.S. tariffs on Chinese goods were slashed from up to 145% to 30%, while China's tariffs on U.S. goods were reduced from 125% to just 10%. This tariff relief was part of broader efforts to ease tensions in the ongoing trade war, which had been a significant source of concern for markets and the potential for economic decline. The easing of tariffs has been particularly favorable for e-commerce companies like Amazon, which no longer face the pressure of passing high tariff-induced costs onto customers. Amazon's stock responded positively, climbing at least 7% after the news broke. The broader market also shared in the optimism, with Reuters reporting the S&P 500 increasing by 2.6%, the Dow Jones up 957 points—or 2.3%—and the Nasdaq gaining 3.6%. Major retail and travel companies similarly benefited, marking a shift towards growth in these sectors. Analysts view Amazon as well-positioned in this adjusted economic environment. Its strategy focuses on maintaining low prices and leveraging its extensive third-party marketplace, which allows it to capture benefits from changing trade patterns. Amazon's adaptability under tariff adjustments appears to strengthen its market positioning, providing it with potential opportunities to expand further in an improving economic scenario.